COMPARISON
Carfilzomib vs Vasopressin
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Carfilzomib is authorised or registered in 10 and Vasopressin in 7 of the 10 registers read. Carfilzomib: highest phase Phase 3 (14 phase 3 trials, 0 with posted results). Vasopressin: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Carfilzomib | Vasopressin | |
|---|---|---|
| Registered trials differs | 308 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: KYPROLIS openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VASOPRESSIN openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2015-11-19 ema · 2026-10-03 | Not checked no record of "authorisedOn" for vasopressin |
| ATC code differs | L01XX45 ema · 2026-10-03 | Not checked no record of "atcCode" for vasopressin |
LEGAL STATUS
Approval in each country read
| Country | Carfilzomib | Vasopressin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.